



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: October 6, 2009

To: Principal Investigators
Primary Clinical Research Associates

From: Linda S. Long
Research Protocol Specialist

Re: N054C, Phase II Study of Sorafenib/Bevacizumab as Salvage Therapy in Patients with Metastatic Colorectal Cancer

At the current rate of accrual, the above trial is expected to reach its accrual goals within 2 weeks or less. When the accrual goals are met, the trial will be temporarily suspended while potential modifications to the study design are considered.

Notification will be sent when accrual is completed and the trial is temporarily suspended.

If you have any questions, please feel free to contact me.